Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company's mission is to translate the promise of RNAi into a new class of transformative medicines for people with rare and prevalent diseases. Founded in 2002, Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, U.S..

Alnylam has pioneered RNAi therapeutics, an innovative approach to gene silencing that targets the genetic causes of disease. Their portfolio of approved RNAi therapeutics includes ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). Additionally, Leqvio (inclisiran) is commercialized by their partner Novartis, and Qfitlia is commercialized by Sanofi. The company's robust pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need across various therapeutic areas, including genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.

Led by CEO Yvonne Greenstreet, who was appointed in January 2022, Alnylam Pharmaceuticals achieved a significant milestone in Q1 2026, reporting over $1 billion in quarterly net product revenues for the first time, largely driven by strong demand for AMVUTTRA, particularly in ATTR cardiomyopathy. The company reiterated its full-year 2026 guidance, projecting total net product revenues between $4.9 billion and $5.3 billion. Alnylam continues to advance a deep pipeline with over 25 active clinical programs, with several key clinical readouts anticipated in the second half of 2026, including the initiation of a Phase 1 trial for ALN-2232 for obesity and weight management.

Latest updates

Alnylam Highlights Vutrisiran's Clinical Profile in ATTR-CM at Heart Failure 2026

Event summary

  • Alnylam will present new data analyses for vutrisiran in ATTR-CM patients at Heart Failure 2026, May 9-12, 2026.
  • Multiple analyses from the Phase 3 HELIOS-B study will underscore vutrisiran's use as a first-line treatment.
  • New insights include pharmacodynamic analysis, safety data, and real-world observational study design.
  • Presentations cover systolic blood pressure influence, atrial fibrillation effects, and vitamin A safety.

The big picture

Alnylam's presentation at Heart Failure 2026 underscores its push to establish vutrisiran as a cornerstone therapy for ATTR-CM, a rapidly progressive and underdiagnosed disease. The focus on real-world data and subgroup analyses reflects the growing emphasis on personalized medicine in cardiovascular care. With over 500,000 estimated cases worldwide, the market potential for effective ATTR-CM treatments remains substantial.

What we're watching

Clinical Validation
Whether the new data will solidify vutrisiran's position as a first-line treatment for ATTR-CM.
Regulatory Pathway
The pace at which Alnylam can secure broader approvals based on real-world evidence from DemonsTTRate.
Competitive Dynamics
How these findings position vutrisiran against emerging therapies in the ATTR-CM space.

Alnylam's Revenue Surges, Nucresiran Trial Expansion Signals Accelerated Growth

Event summary

  • Alnylam reported $1.17 billion in total revenue for Q1 2026, a 96% increase year-over-year.
  • AMVUTTRA and ONPATTRO generated $910 million and $20 million in net product revenues, respectively, representing 153% total TTR growth.
  • The Phase 3 TRITON-CM trial for nucresiran is expanding enrollment from 1,250 to 1,750 patients due to faster-than-anticipated recruitment.
  • Alnylam initiated a Phase 1 trial for ALN-2232, an adipose-targeted RNAi therapeutic for obesity and weight management.

The big picture

Alnylam's strong Q1 2026 results underscore the growing demand for RNAi therapeutics, particularly in rare diseases like ATTR amyloidosis. The expansion of the nucresiran trial and entry into the obesity market signal an aggressive growth strategy, but also introduce new execution risks. The company's ability to maintain its leadership position will depend on successfully navigating regulatory hurdles, managing competition, and demonstrating the long-term value of its pipeline.

What we're watching

Enrollment Pace
The accelerated enrollment in the TRITON-CM trial suggests a higher-than-expected demand for ATTR-CM therapies, potentially impacting nucresiran's launch timeline and competitive landscape.
Adipose Targeting
The initiation of the ALN-2232 Phase 1 trial marks Alnylam's foray into the obesity market, a space attracting significant investment and scrutiny, and its success will hinge on demonstrating efficacy and safety in a complex biological environment.
Commercial Dynamics
The continued growth of AMVUTTRA, despite ONPATTRO's decline, will be critical to sustaining Alnylam's overall revenue trajectory and will require ongoing market differentiation and patient access strategies.
CID: 3551